Baycox Bovis 50 mg/ml Oral Suspension

Ország: Egyesült Királyság

Nyelv: angol

Forrás: VMD (Veterinary Medicines Directorate)

Aktív összetevők:

Toltrazuril

Beszerezhető a:

Bayer plc

ATC-kód:

QP51AJ01

INN (nemzetközi neve):

Toltrazuril

Engedélyezési státusz:

Expired

Termékjellemzők

Revised: February 2012
AN: 01156/2011
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Baycox Bovis 50 mg/ml oral suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
Active substance:
Toltrazuril
50.0 mg
EXCIPIENT(S):
Sodium benzoate (E211)
2.1 mg
Sodium propionate (E281)
2.1 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
White or yellowish suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (calves on dairy farms)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the prevention of clinical signs of coccidiosis and reduction of
coccidia shedding
in housed calves replacing cows producing milk for human consumption
(dairy cows)
on farms with a confirmed history of coccidiosis caused by _Eimeria
bovis_ or _Eimeria _
_zuernii_.
4.3
CONTRAINDICATIONS
For environmental reasons:

Do not use in calves weighing more than 80 kg bodyweight.

Do not use in fattening units such as veal or beef calves

For more details see sections 4.5, other precautions and section 5,
environmental
properties.
Revised: February 2012
AN: 01156/2011
Page 2 of 5
4.4
SPECIAL WARNINGS

As with any antiparasiticide frequent and repeated use of
antiprotozoals from the
same class may lead to the development of resistance.

It is recommended to treat all calves in a pen

Hygienic measures may reduce the risk of bovine coccidiosis. It is
therefore,
recommended to improve concomitantly the hygienic conditions in the
concerned
facility, particularly dryness and cleanliness.

To obtain maximum benefit, animals should be treated before the
expected onset
of clinical signs, i.e. in the prepatent period.

To alter the course of an established clinical coccidial infection, in
individual
animals already showing signs of diarrhoea, additional supportive
therapy may be
required.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
None
ii.
Special precautions to be taken by